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Abstract
Background: Spirulina maxima is a filamentous cyanobacterium used as food supplement because
of its high nutrient contents. It has been experimentally proven, in vivo and in vitro that posses
several pharmacological properties. The purpose of this study was to evaluate the effects of
Spirulina maxima orally supplied (4.5 g/day, for 6 weeks) to a sample of 36 subjects (16 men and 20
women, with ages between 18–65 years) on serum lipids, glucose, aminotransferases and on blood
pressure. The volunteers did not modify their dietary habits or lifestyle during the whole
experimental period. From each subject, a sample of blood was drawn in fasting state of 12 hours
to determi the plasma concentrations of glucose, triacylglycerols (TAG), total cholesterol (TC),
cholesterol associated to high density lipoprotein (HDL-C) and aspartate aminotransferase (AST).
Anthropometric measurements including systolic (SYST-P) and diastolic (DIAST-P) blood pressure,
height, weight and Body Mass Index (BMI) were also recorded.
Results: Comparing initial and final data, the results showed that there were no significant changes
in the values of glucose and AST, but significant differences in TAG, TC, and HDL-C, were
observed: TAG 233.7 ± 177.8 vs. 167.7 ± 100.7 mg/dL (p < 0.001), TC 181.7 ± 37.5 vs. 163.5 ±
34.4 mg/dL (p < 0.001), C-HDL 43.5 ± 14.4 vs. 50 ± 18.8 mg/dL (p < 0.01). The univariated analysis
showed that the changes in the HDL-C and TC concentrations were dependent on TAG
concentration (p = 0.247 and p = 0.108, respectively); nevertheless the calculated values for
cholesterol associated to low density lipoprotein (LDL-C) were significantly reduced by the
Spirulina maxima treatment but independently of the TAG changes. In addition, significant
differences were found comparing initial and final SYST-P and DIAST-P blood pressure in both male
and female: SYST-P male 121 ± 9 vs. 111 ± 8 mm Hg (p < 0.01), DIAST-P male 85 ± 6.5 vs. 77 ± 9
mm Hg (p < 0.01); SYST-P female 120 ± 9.5 vs. 109 ± 11 mm Hg (p < 0.002), DIAST-P female 85
± 11 vs. 79 ± 7.5 mm Hg (p < 0.03).
Conclusion: The Spirulina maxima showed a hypolipemic effect, especially on the TAG and the
LDL-C concentrations but indirectly on TC and HDL-C values. It also reduces systolic and diastolic
blood pressure.
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Chronic-degenerative diseases are a growingly health
problem all over the world [1]. In Mexico, coronary heart
disease and diabetes mellitus are the first and second lead-
ing causes of death between general population according
to Statistics, Geography and Informatics' National Insti-
tute (INEGI) [2]. This has been related with recognized
environmental factors as a high caloric diet intake, leak of
exercise, tobacco and alcohol consumption and genetic
predisposition [3-7]. It is well known that the modifica-
tion on lipid concentration is a useful approach to
decrease cardiovascular mortality through prevention on
development of atherosclerotic disease [8-13].
Spirulina maxima, a filamentous and unicellular alga is a
cyanobacterium belonging to the Oscillatoraceae family
that usually grows in the alkaline waters of Africa, Asia,
North and South America [14]. Spirulina has been used as
food additive because of its high content of proteins as
well as essential nutrients like carotenoids, vitamins and
minerals [15-17]. In addition, previous studies have dem-
onstrated its several biological activities such as inhibit
viral replication [15,18,19], prevent anemia [20], decrease
genotoxicity induced by drugs [21], prevent fatty liver dis-
ease [22-25] and has hypoglycemic [26] and hypolipemic
properties [27-30]. It has also been studied its effects on
vasomotor responses on aortic rings proposing its antihy-
pertensive activities in experimental models [31-33]. At
this point, only few studies have evaluated these effects on
human population.
The purpose of this study was to evaluate the effects of
Spirulina maxima, orally administered, on serum lipids
and blood pressure in a Mexican population after six
weeks of treatment, as a possible alternative treatment for
dyslipidemia and hypertension.
Results
No changes were observed on AST and glucose values
throughout the experimental period (35 ± 18 UI/L and 85
± 13 mg/dL respectively, results not shown). On the other
hand, as shown in Table 1, the initial concentration of lip-
ids did not differ significantly between male (n = 16) and
female (n = 20), suggesting their possible association as a
single group. Because of the initial triacylglycerol concen-
trations were 254 ± 173 and 217 ± 184 mg/dL, for male
and female groups, respectively, the values suggest a
hypertriacylglycerolemic tendency in the studied sample.
The other lipid values were in the optimal or limit ranges.
In addition, both initial systolic and diastolic blood pres-
sures did not differ significantly between male and
female.
At the end of the experimental period there were signifi-
cant differences in blood lipids after the Spirulina treat-
ment (Table 2). Plasma TAG and TC concentrations were
the most diminished (p = 0.001, Mann-Whitney and Stu-
dent's-t tests) but LDL-C concentrations were also
decreased (p = 0.01, Student's-t test), and HDL-C values
were increased (p = 0.01, paired Mann-Whitney test).
However, the univariate analysis showed that the changes
on HDL-C and TC concentrations were dependent on
TAG concentration (p = 0.247 and p = 0.108, respec-
tively); while LDL-C concentration was independent of
TAG values (p = 0.044). As mentioned before, there were
no differences between initial and final AST or glucose
concentration. Respect on blood pressure (Table 2) it was
shown a significant difference between initial and final
systolic and diastolic blood pressure records (p < 0.001
SYST-P; p < 0.05 DIAST-P, Tukey's comparison test). Fur-
thermore, a significant decrease on systolic blood pressure
was observed since the fourth week of Spirulina consump-
tion (initial SYST-P 121 ± 9 vs. fourth week SYST-P 114 ±
10 mmHg, p < 0.05; vs. fifth week SYST-P 112 ± 8 mmHg,
p < 0.01).
Dyslipidemia Prevalences
On the other hand, when the effects of Spirulina on dysli-
pidemia prevalences were assessed, the results (Table 3)
show that the initial hypercholesterolemia prevalence (TC
≥ 200 mg/dL) was of 27.8%, but it was diminished after
the treatment to 13.9%. The most important changes were
observed if the higher values of cholesterol (TC ≥ 240 mg/
dL) were used for the analysis of hypercholesterolemia,
the initial prevalence was 8.3%; and after the Spirulina
treatment was 0.0%. Initial hypoalphalipoproteinemia
prevalence was 27.7% (10/36, cases); and at the end of
treatment, prevalence was only 22.0% (8/36 cases). The
initial prevalence of hypertriacylglycerolemia in the sam-
ple was 41.7% versus a final prevalence of 22.2%. Further-
more, significant differences were found between male
and female groups (initial hypertriacylglycerolemia prev-
Table 1: Basal Values in the sample, by gender
TAG (mg/dL) TC (mg/dL) HDL-C (mg/dL) LDL-C (mg/dL) SYST- P (mmHg) DIAST-P (mmHg)
M 254 ± 173 177 ± 39 39 ± 13 100 ± 37 121 ± 9 85 ± 6.5
F 217 ± 184 186 ± 37 44 ± 15 112 ± 25 120 ± 9.5 85 ± 11
p 0.89 0.647 0.588 0.5 0.586 0.185
Values are mean ± SD. M, male; F, female. TAG, triacylglycerols; TC, total cholesterol; HDL-C, high density lipoprotein-cholesterol; LDL-C, low 
density lipoprotein-cholesterol. p: significance value, Student's-t test.Page 2 of 8
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43.8% vs. 5%, p = 0.008, respectively).
Dyslipidemia prevalences were analyzed in age terciles,
with middle age groups of 29.3 ± 5.4 (18–38 years), 43.8
± 2.7 (39–46 years) and 55.9 ± 5.9 (49–65 years). The
results showed that according to the initial values, all of
the groups showed hypertriacylglycerolemia cases with
predominance (6/36) in the last group (49 to 65 years)
whereas most hypercholesterolemic (6 or 3/36, CT >200
or 240 mg/dL, respectively) and hyperbetalipoproteine-
mic cases (5/36) belong to age group of 39–46 years. After
the Spirulina treatment, the results showed that the eldest
age group (49–65 years) was most responsive to the treat-
ment (p < 0.001). The average change in TAG and TC val-
ues after treatment was -20% (-44 to -4, confidence
intervals 95%) and -8% (-24 to -2, confidence intervals
95%), respectively. An increase tendency 27% on HDL-C
concentration for all groups (5 to 50, confidence intervals
of 95%) was observed.
High Blood pressure prevalence
According JNC 7 blood pressure reference values, high
blood pressure prevalence was assessed in total sample
before and after treatment with Spirulina (Table 4). The
results show that the initial Hypertension type 2 preva-
lence was 14% (5/36 cases), but it was diminished after
the treatment to 3% (1/36 case), whereas Hypertension
type 1 prevalence diminished from 31% (11/36 cases) to
11% (4/36 cases). Furthermore, an increase on pre-hyper-
tension prevalence from 44% (16/36 cases) to 50% (18/
36 cases) and normal blood pressure prevalence from
11% (4/36 cases) to 36% (13/36 cases) were found.
Prevalences were analyzed by gender (Table 5). The results
showed an initial high prevalence of Stage 1 of Hyperten-
sion in both male and female population (30% and 31%,
respectively) that was decreased after treatment in both
(6% and 15%, respectively) and in the case of stage 2 of
hypertension, prevalence in men was decreased from 6%
to 0% and in female was reduced from 20% to 5%. The
most significant decrement in blood pressure was
observed in the youngest group (18 – 38 years; p < 0.001),
with an average change in SYST-P and DIAST-P of -8% (-
17 to -3, confidence intervals 95%) and -6% (-12 to -1,
confidence intervals 95%), respectively.
Discussion
Previous studies have demonstrated the hypolipemic
activity of Spirulina maxima in rats with and without toxic
substances [27-30]. Using a single intraperitoneal dose of
2 mL/kg carbon tetrachloride (CCl4) as an hepatotoxic in
order to induce non alcoholic steatohepatitis, it was dem-
ostrated that 5% Spirulina maxima in diet decrease serum
AST, liver TAG and TC in rats. The same pattern was
observed in the liver free fatty acids (with an important
decrease on unsaturated fatty acids) and thiobarbituric
acid reactive substances [24]. These results suggest that
Spirulina has hepatoprotective properties through decreas-
ing on liver lipid profile and lipoperoxidation products.
At this way, it has been demonstrated that Spirulina
maxima prevents the development of fatty liver induced by
Table 2: Values of the studied variables, before and after Spirulina treatment
Variable TAG (mg/dL) TC (mg/dL) HDL-C (mg/dL) LDL-C (mg/dL) SYST-P (mmHg) DIAST-P (mmHg)
Initial 234 ± 178 182 ± 37 43 ± 14 103 ± 30 120 ± 9 85 ± 9
Final 168 ± 101 163 ± 34 50 ± 19 86 ± 28 109 ± 9 79 ± 8
p 0.001a 0.001a 0.01a 0.013a < 0.001b <0.05b
Univar. p 0.108 0.247 0.044
Values are mean ± SD; n = 36; a Student's t test or b Tuckey's multiple comparison test; Univar. p = univariated p. p: significance value.
Table 3: Dyslipidemia prevalence in the sample (cases)
Variable TAG* (mg/dL) TC* (mg/dL) HDL-C* (mg/dL) LDL-C* (mg/dL)
<200 >200 <(200/240) >(200/240) <35 >35 <130 >130
Initial (n = 
36)
21 15 26/33 10/3 10 26 27 9
Final (n = 
36)
28 8 31/36 5/0 8 28 33 3
* p < 0.05 initial vs. final, chi-squared testPage 3 of 8
(page number not for citation purposes)
Lipids in Health and Disease 2007, 6:33 http://www.lipidworld.com/content/6/1/33simvastatin, ethanol and hypercholesterolemic diet in
mice [29].
As previously mentionated, the purpose of this study was
to evaluate the effects of Spirulina on human lipid metab-
olism and blood pressure levels. Parikh P et al., studied
the effect of Spirulina supplementation at 2 g/day doses
for two months on blood glucose levels, glycosylated
hemoglobin and lipid profile of twenty-five diabetic type
2 subjects [26]. They found a lowering of fasting and post-
prandial blood glucose levels and in the HbA1c level; this
findings contrast with our results, where glucose levels
kept stable during all studied period. Respect on lipid pro-
file, the same report demonstrates a reduction on TAG, TC
and in the atherogenic indices TC/HDL-C and LDL-C/
HDL-C. Samuels R et al., also observed these effects in
patients with hyperlipidemic nephrotic syndrome after
supplementation with 1 g/day in the same period [34].
In our study, TAG, TC and LDL-C showed a significant
reduction with an increase on HDL-C concentration after
a study period of six weeks. However, changes on TC and
HDL-C were dependent in TAG concentration, mean-
while LDL-C values decreased after treatment in an inde-
pendent way. Before treatment, a high prevalence of
hypercholesterolemia (27.8%, > 200 mg/dL), hypertria-
cylglycerolemia (41.7%) and hypoalphalipoproteinemia
(27.7%) was found; this observation contrast with a Mex-
ican nationwide previous study where hypertriacylglycer-
olemia was the second most common dyslipidemia
(24.3%) after hypoalphalipoproteinemia (46.2% for men
and 28.7% for women) [35]; however, the prevalence of
hypercholesterolemia was similar to that reported in a
more recent study (26.5%) [36]. At this point, after treat-
ment it was observed a significant decrease in all preva-
lence parameters studied with a major effect observed in
the oldest age group (49–65 years). This is very important
because a lot of chronic-degenerative disorders related
with dyslipidemia, incrementing their prevalence in this
age group [1,13,37,38], could be attenuated with Spirulina
consumption.
With regard to blood pressure, only 11% of studied pop-
ulation had normal levels before treatment, whereas 44%
prehypertension, 31% hypertension stage 1 and 14% a
stage 2. The hypertension prevalence on Mexican people
has shown a clear increasing trend, 13.4% on 2000 survey
to 22.7% on 2006 survey, indicating that the present prev-
alence (45%) could not represent the nationwide values
[36]. According the Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (JNC 7) criteria [39],
patients with prehypertension or hypertension in any
stage, have to include in their treatment a balanced diet
and exercise. Several natural products have been used to
help in the treatment of hypertensive patients. Lima-
Landman et al., in normal and hypertensive rats demon-
strated that an aqueous extract of dried leaves from
Cecropia glaziovii Sneth had an antihypertensive effect [40].
Ojewole J et al., showed that Persea americana Mill aque-
ous leaf extract (25–800 mg/mL) caused bradycardia,
vasorelaxation and hypotension in mammalian experi-
mental models in response to a possibly increased synthe-
sis and release of nitiric oxide [41]. After supplementation
with Spirulina it was observed 14% hypertension preva-
lence, 36% patients reached a normal blood pressure
whereas patients with hypertension stage 1 or 2 decreased
their levels to prehypertension (50%). These changes were
observed in men and women, and that youngest group
was more blood pressure responsive to Spirulina than the
other age groups (data not shown).
The action mechanisms of Spirulina on lipid metabolism
and blood pressure are not well understood yet. Nagakoa
S et al., found that a concentrate of Spirulina platensis
inhibited jejunal cholesterol absorption and ileal bile acid
Table 4: Initial and Final High Blood Pressure Prevalences* (%)
BP Normal Prehypertension Hypertension Stage 1 Hypertension Stage 2
Initial 11 44 31 14
Final 36 50 11 3
BP: blood pressure. * p = 0.01 initial vs. final, chi-squared test, n = 36.
Table 5: High Blood Pressures Prevalences by gender, cases (%)
Normal Prehypertension Stage 1 Hypertension Stage 2 Hypertension
Male, initial 1 (6%) 9 (57%) 5 (31%) 1 (6%)
Male, final 6 (38%) 9 (56%) 1 (6%) 0 (0%)
Female, initial 3 (15%) 7 (35%) 6 (30%) 4 (20%)
Female, final 7 (35%) 9 (45%) 3 (15%) 1 (5%)Page 4 of 8
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ecule responsible for this effect [42]. Li-Kun H et al., iso-
lated an active component designed as glycolipid H-b2
and they found that this glycolipid inhibits pancreatic
lipase activity in a dose-dependent manner, lowering rat
plasma TAG levels [43]. Furthermore, they found that
phycocyanin inhibits pancreatic lipase at the same way.
These effects could explain the hypocholesterolemic and
hypotriacylglycerolemic effects seen on Spirulina maxima,
treated patients, but no studies have been conduced at the
moment.
On other hand, a diet supplemented with Spirulina
maxima has showed to prevent synthesis and release of
vasoconstricting metabolites of arachidonic acid induced
by fructose and attenuates tension development in
response to phenylephrine [33]. Other reports, using an
ethanolic extract, demonstrated an increased nitric oxide
endothelium synthesis/release, a well known vasodilata-
tion metabolite [31]. At this point, it's well known that
blood pressure could be increased in patients that develop
vasoconstriction in response to certain metabolites or due
to atherosclerotic process [44]. Hypotension observed on
patients could be explained on these effects. Hsiao G et al.,
have proposed that C-phycocyanin inhibits platelet aggre-
gation through inhibition of calcium mobilization and
mediation of free radicals released by platelet [45]. These
could be supported by a well recognized effect of Spirulina
mediating several steps on inflammation process that
finally reduces atherotrombotic plaque formation. Guan
Y et al., have also proposed that high potassium, and low
sodium contents of Spirulina, have positive effects on
blood pressure [46]. We found that supplementation with
Spìrulina decreases LDL-C and increases HDL-C with a
probably beneficial effect on atherotrombotic indices.
Finally, our results also supported vasodilatation theory,
as seen in a major effect of Spirulina in diastolic blood
pressure mainly determinated by peripherical vessel
resistance.
Actually, statins are recognized as the first-line therapy for
cholesterol lowering. In a study conduced by Berne in type
2 diabetic patients, prescription of rosuvastatin (10 mg/
day) by 4 weeks decreased significatively LDL-C levels in
a mean percentage of 47.6%, TC in 33.6%, TAG in 19.2%
and increased HDL-C in 4.4%, and demonstrated more
response on lipid profile in comparison with atorvastatin
at the same dose [47]. Rangineni V et al., using dried
Eclipta alba leaf powder (3 g/day) in mild hypertensive
subjects, observed a reduction on LDL-C, TC and TAG
with mean percentages of 24%, 17% and 14%, respec-
tively [48]. As mentionated before, treatment with Spir-
ulina maxima, decreased significatively LDL-C, TC and
TAG in a mean percentage of 17%, 8% and 20%, respec-
tively, and increased HDL-C in 27%. These results support
that Spirulina maxima could be used as an effective supple-
ment on hypertriacilglycerolemic patients.
Respect of blood pressure, dried extract of Hibiscus sabdar-
iffa, a widely used herbal medicinal product adminis-
trated for 4 weeks, decreased systolic and diastolic blood
pressure in 11.58% and 12.21%, respectively [49]. At this
way, Eclipta alba dried leaf powder reduced mean arterial
pressure by 15% [48]. After treatment with Spirulina
maxima, systolic and diastolic blood pressure decreased in
a mean percentage of 8% and 6%, these results suggest
that Spirulina maxima could be used as a supplement on
blood pressure lowering therapy; however, these findings
deserve more research in view that our study was per-
formed in an open sample, non-representative and small
population.
Finally, security on the use of Spirulina was demonstrated
with no AST levels elevation trough evaluation period.
There were no reports of adverse effects on population
studied. Only idiosyncratic adaptative effects as: head-
ache, flatulence, metheorism and increase of intestinal
transit (not diarrhea) were reported on the first week of
treatment. This is according with other reports where secu-
rity of oral administration was studied [50-52].
Conclusion
The present results demonstrate that Spirulina maxima has
hypolipemic effects, especially on the TAG concentration
and the LDL-C but indirectly on TC and HDL-C values
and positive effects on lowering blood pressure. We pro-
pose that because of these pharmacological properties,
Spirulina could be used as a dietary supplement on dysli-
pidemic and hypertensive patients.
Materials and methods
Subjects
Sixty five adult volunteers of both genders were invited to
participate in the experiment. All of them met the follow-
ing inclusion criteria: Mexico City inhabitant, age ≥ 18
years old, engagement to complete the treatment, not
known cardiovascular disease and not taking at the time
of the study drugs known to affect lipid metabolism or
blood pressure values, not even oral antidiabetic drugs or
insulin. Individuals with Renal Failure or Hepatic Disease
were excluded. Only thirty six participants concluded the
evaluation period. The final participants were sixteen
male and twenty female. The protocol and the aim of the
study were fully explained to the subjects, who gave their
written consent. The research was carried out in accord-
ance with the Declaration of Helsinki and was approved
by the Ethics Committee of the School of Medicine,
UNAM, Mexico D.F.Page 5 of 8
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It was determined an evaluation period of six weeks in
order to observe changes on lipid levels before and after
treatment with Spirulina maxima. During this time all vol-
unteers were asked not to modify dietary habits or lifestyle
to minimize the effects on lipids metabolism. At the
beginning of the study and every week, blood samples
were taken in the morning after a 12 h fasting and 15 min
of rest, using blood collection tubes (BD Vacutainer) in
order to observe initial and final levels on glucose, TAG,
TC, HDL-C, and weekly AST levels to asses the non-hepa-
totoxical effect of treatment. Systolic and diastolic blood
pressure, height and weight were also registered, and BMI
was calculated. Spirulina maxima was orally consumed, 4.5
g/day (tablets of 0.5 g, 3 tablets each 8 hours approxi-
mately) for six weeks. The Spirulina used in this study was
purchased from Spiral Spring, Mexico. The valuated com-
position of the tablet was: protein 57.35%, lipids 5.44 %
(ether extract), ash 11.41 %, fiber 0.41 % and carbohy-
drates 25.33% on dry base analyses.
The prevalence of hyperlipidemia was registered both
before and after the experimental period. Hypercholester-
olemia was defined as TC levels more than 200 mg/dL or
240 mg/dL, according to Adult Treatment Panel (ATPIII or
ATPII) recommendations [53,54]. Hypoalphalipopro-
teinemia was defined as lower HDL-C values than 35 mg/
dl, according to ATPII recommendations. Hypertriacylg-
lycerolemia was defined as higher TAG values than 200
mg/dL, according to ATPII recommendations. Hyperbe-
talipoproteinemia was defined as higher LDL-C values
than 130 mg/dL, according to ATPIII recommendations.
Normal blood pressure was defined as values less than
120/80 mmHg for SYST-P and DIAST-P blood pressure,
respectively. Prehypertension was defined as values of
SYST-P blood pressure of 120–139 mmHg or DIAST-P
blood pressure of 80–89 mmHg. Stage 1 of hypertension
was defined as values of 140–159 mmHg for SYST-P
blood pressure or 90–99 mmHg for DIAST-P blood pres-
sure, meanwhile stage 2 was defined as higher values than
160/100 mmHg for SYST-P and DIAST-P blood pressure
respectively, according criteria from The Seventh Report of
the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure (JNC
7) [39].
Anthropometric measurements
The height was measured using a rigid stadiometer.
Weight of subjects, in light clothing, was measured in a
calibrated balance scale. BMI was calculated as the weight
(kg) divided by the height (m) squared (kg/m2). Blood
pressure was measured using a sphygmomanometer by
auscultatory method. Anthropometrical details of subjects
are shown in Table 6.
Laboratory analyses
Blood for plasma analyses was drawn into 100 units
sodium heparin (USP) freeze-dried sterile glass tubes (BD
Vacutainer) and centrifuged at 4,000 × g for 5 minutes at
4°C. Total cholesterol and TAG concentrations were ana-
lyzed by using standard enzymatic procedures (Jas Diag-
nostics, Inc. Mexico) with a spectrophotometer (Genesys
10 UV, Thermo Electron Corporation, USA); HDL-C con-
centration was measured after precipitation of apo B-con-
taining lipoproteins with precipitation reactive (Roche,
Mexico); LDL-C concentration was determined by using
the Friedewald's formula modified by De Long D et al.
[55]; AST and glucose were measured with an enzymatic
kit (Merck, Mexico) by spectrophotometry methods.
Statistical analysis
Frequency distribution for variables was determined by
Kolmogorov-Smirnov test. Comparisons between groups
were done using Student's t test, Mann-Whitney's test or
Tukey's multiple comparison test, when appropriate. In
order to evaluate dependency of TAG changes, univariated
analysis was performed. Significant differences between
prevalences were assessed with Chi-squared test using
contingency tables. Statistical analyses were performed
using SPSS for Windows software (version 10.0). Results
are expressed as mean ± S.D.
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